FDA approves Amgen’s XGEVA® (denosumab) for the treatment of giant cell tumor of bone
13 June 2013 | By Amgen
XGEVA becomes first FDA-approved treatment for this rare disease...
List view / Grid view
News
Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients
13 June 2013 | By Boehringer Ingelheim
Data from interferon-free SOUND-C3 study...
Roche’s RoACTEMRA shows long-term efficacy in monotherapy and also benefits in early rheumatoid arthritis
13 June 2013 | By Roche
Roche announced data from two phase III studies...
bioMérieux Industry celebrates the 10th anniversary of BioBall®
12 June 2013 | By bioMérieux
A wide range of BioBall® products to meet diverse customer needs...
Amgen announces top-line results of Phase 3 Trebananib (AMG 386) TRINOVA-1 trial in recurrent ovarian cancer
12 June 2013 | By Amgen
Study meets primary endpoint of progression-free survival...
Amgen and Cytokinetics announce expansion of license for Omecamtiv Mecarbil
12 June 2013 | By Amgen
Amgen and Cytokinetics announced an expansion of their strategic collaboration...
Merck welcomes independent review of the safety profile of JANUVIA® (sitagliptin)
12 June 2013 | By Merck
"Nothing is more important to Merck than the safety of our medicines..."
AbbVie presents first study assessing the role of predefined doses of methotrexate when used in combination with HUMIRA® (adalimumab) for RA
12 June 2013 | By AbbVie
Results from the CONCERTO trial...
Abbott initiates randomized clinical trial in Japan to evaluate the Absorb™ Bioresorbable Vascular Scaffold
11 June 2013 | By Abbott
Trial to study the innovative "dissolving" heart device...
New four-strain influenza vaccine from Sanofi Pasteur now licensed by FDA for broad age range of children and adults
10 June 2013 | By Sanofi Pasteur
“Sanofi Pasteur is committed to providing new immunization options..."
Roche’s RoACTEMRA approved in EU to treat children with rare form of arthritis
10 June 2013 | By Roche
“This approval comes earlier than expected, just one month following the positive CHMP opinion...”
Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with MS
10 June 2013 | By Novartis
Two new analyses from the Phase III TRANSFORMS study presented...
AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
10 June 2013 | By AstraZeneca
AstraZeneca has entered into a definitive agreement to acquire Pearl Therapeutics...
Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia
8 June 2013 | By Boehringer Ingelheim
New findings presented...
Gilead announces U.S. FDA priority review designation for sofosbuvir for the treatment of hepatitis C
7 June 2013 | By Gilead Sciences
Gilead Sciences announced that the U.S. FDA has granted priority review...
